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ABSTRACT 
Transdermal drug delivery has had a rich past and is now emerging as a major alternative to other delivery systems. As this technique has 
matured and new fundamentals have been integrated into its development, new products and applications have shown new ways in which skin 
can play a larger part in healthcare and quality of life. Improved delivery has been shown for drugs of differing.  The cumulative percentage of 
drug released in 12 h was found to be minimum and maximum for the formulations F4 and F10 i.e. 81.023 ± 3.013 % and 98.564 ±3.005%.The 
results of the drug content in all the formulations were found to be in the range of 96 to 98 %. The maximum moisture loss was 4.3300 ± 0.0360 
%. The prepared film had tendency to absorb moisture effectively. Glibenclamide is a third generation oral anti-diabetic sulphonylurea drug 
frequently prescribed to patients of type 2 diabetes. Glibenclamide therapy improves postprandial insulin/C-peptide response, and 
overall glycaemia control. The development of Glibenclamide transdermal patch for anti-diabetic will be an excellent dosage form for market 
strategy due to its very fast action and better patient compliance. 
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INTRODUCTION 
Glibenclamide is a third generation oral anti-
diabetic sulphonylurea drug frequently prescribed to 
patients of type 2 diabetes. Glibenclamide therapy improves 
postprandial insulin/C-peptide response, and 
overall glycaemia control. The problem arrived by the 
oral Glibenclamide therapy upon the bioavailability due to its 
poor solubility leading to irreproducible clinical response, in 
addition to adverse effects like dizziness and gastric 
disturbances [1]. As a potential for convenient, safe and 
effective anti-diabetic therapy, the transdermal delivery 
system for Glibenclamide was being developed. 
Glibenclamide is an anti-diabetic drug in a class of 
medications known as sulfonylureas. It is also sold in 
combination with metformin under the trade name 
Glucovance. Glibenclamide exerts pancreatic and 
extrapancreatic actions. It stimulates an increase in insulin 
release by the pancreatic β-cells. It may also reduce 
hepatic gluconeogenesis and glycogenolysis. Increased 
glucose uptake in the liver and utilization in the skeletal 
muscles[2]. 
Many drugs from natural[3–5] and synthetic sources have 
been formulated in transdermal drug delivery systems e.g., 
nicotine, anti-histamines, beta-blockers, NSAIDS, calcium 
channel blockers, contraceptives, anti-arrhythmic drugs, 
insulin, anti-viral drugs, hormones, interferon’s and anti-
cancer agents etc. In 1969 first US Patent (US 3426754) on 
transdermal drug delivery device was issued to Bierenbaum 
et al., 1969 for the invention of breathable medical dressing. 
Stability and skin permeation of salbutamol base from 
adhesive matrix transdermal patches containing antioxidants 
and skin permeation enhancers were studied. Optimal 
therapy of a disease requires an efficient delivery of active 
drug to the tissues, organs that need treatments. Very often 
dosed far in excess to those required in the cells have to be 
administered in order to achieve necessary therapeutically 
effective concentration. This unfortunately may lead to 
toxicological, undesirable and immunological effects in non-
target tissue and takes a lot of time. A transdermal patch is 
lead to better management of the disease condition with very 
fast action.Development of a transdermal patch’s demands 
considerable understanding of the amount of drug. TDDS is 
limited by the amount of drug that can be incorporated into 
each unit dose, and another factor is mechanical strength. In 
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order to allow tdds  they are made of either very porous & 
soft-molded matrices of compressed into patch’s with very 
low compression force, which makes the  easy handle on the 
transdermal route [6].The development of Glibenclamide 
transdermal patch for anti-diabetic will be an excellent 
dosage form for market strategy due to its very fast action 
and better patient compliance. 
MATERIALS AND METHODS 
Chemicals 
Glibenclamide was kindly provided by Delta Pharma. Co. 
(Mumbai, India). Chitosan (MW 150,000, deacetylation 
degree 75–85%), β-cyclodextrin, cineole, menthol, limonene 
and streptozotocin were purchased from Sigma Chemical 
Company (St. Louis, USA). Oleic acid was purchased from 
Fluka (Germany). Sodium dihydrogen phosphate was 
supplied from S. D. fine-chem. Ltd. (Mumbai, India) and 
disodium hydrogen phosphate was purchased from BDH 
Laboratory Supplies (Poole England). Lactic acid, acetic acid 
and ethanol were supplied from Adwic, Banglore. All other 
ingredients are of analytical grade. 
Preparation of Glibenclamide-cyclodextrin complex 
The continuous variation method 29 was utilized to 
determine the stoichiometric ratio of Glibenclamide-β-CyD 
complex by spectrophotometric measurements. The 
absorbance values of fixed total concentration (0.072 
mmol/l) of Glibenclamide and β-CyD were measured at 226 
nm. If it was found that the absorbance values of these 
solutions were different from the sum of the corresponding 
values of their components. 
Preparation of Chitosan Films 
Chitosan (1.5% w/v) was dissolved in water containing 2 % 
w/v of a 1:1 mixture of lactic acid and acetic acid solution 
and stirred overnight using a magnetic stirrer. The resulting 
solution was filtered through a sintered glass filter to remove 
the extraneous matter. The resulting solution was medicated 
with the drug or its equivalent amount of the Glibenclamide 
complex followed by sonication for 2 hours. Two 
concentrations of Glibenclamide were used in preparing the 
films[7]. 
Characterization 
 Physical Appearance 
All the prepared patches were visually inspected for color, 
clarity, flexibility and smoothness[8]. 
 Thickness Uniformity 
The thickness of the formulated film was measured at 3 
different points using a mitutoya thickness guage 7301 made 
in Japan thickness of three reading was calculated. Average 
thickness was determined[8]. 
 Folding Endurance 
The folding endurance was determined to determine 
flexibility of film. The flexibility of the film is needed to 
handle the film easily and for comfortable, secured 
application of film on the wound. It was determined by 
repeatedly folding one film at same place till it breaks or 
folded up to 300 times manually. The number of times of film 
could be folded at the same place withoutbreaking give the 
value of folding endurance[8]. 
 Water Absorption Capacity 
It is of utmost importance, if they are used for biological 
applications and wound healing. It is used to measure the 
capacity of film to absorb wound exudates. The initial weight 
of 1inch of dry film was noted. Then this film was placed in 
15ml. of distilled water taken in Petri plate. The weight of the 
film was noted periodically at first hour, second hour, third 
hour and 24th hour. Every time after noting the weight, the 
film was placed in fresh water[9]. Water absorption capacity 
of the film was calculated using a formula: 
                     
                         
             
     
 Percentage Moisture Loss 
The films were weighed accurately and kept in a desiccators 
containing anhydrous calcium chloride. After 3 days, the 
films were taken out and weighed[9]. The moisture loss was 
calculated using the formula:  
               
                         
             
     
 Water Vapor Transmission Rate 
Glass vials of 5 ml capacity were washed thoroughly and 
dried to a constant weight in an oven. About 1 g of fused 
calcium chloride was taken in the vials and the polymer films 
of 2.25 cm2 were fixed over the brim with the help of an 
adhesive tape. Then the vials were weighed and stored in a 
humidity chamber of 80-90 % RH condition for a period of 
24 h[10]. The vials were removed and weighed at 24 h time 
intervals to note down the weight gain. 
                  
                         
             
     
 Tensile strength 
Tensile strength of the film was determined with Universal 
strength testing machine (JUSTY, Tensile Testing Machine, 
JTM 50 digital). The sensitivity of the machine was 1 g. It 
consisted of two load cell grips. The lower one was fixed and 
upper one was movable. The test film of size (10 × 10 mm2) 
was fixed between these cell grips and force was gradually 
applied till the film broke[10]. The tensile strength of the film 
was taken directly from the dial reading in kg. Tensile 
strength is expressed as follows: 
                 
                      
                    
 
 Drug content 
An accurately cut patch of 1cm2 area was taken and added to 
a beaker containing 1 ml phosphate buffer solution of pH 7.4 
The beaker was kept 24 hours with occasion shaking[10]. The 
sample was analyzed drug content using UV 
spectrophotometer 248nm.This study was performed for 3 
times for a single patch. 
 In vitro Drug Release Studies 
The in vitro evaluation was carried out in the modified Franz 
diffusion cell. This consists of an upper donor compartment 
and the lower receptor compartment, surrounded by water 
jacket for circulation of water to maintain the temperature 
inside at 32±1.0C.The uniformity of solution in the receptor 
phase was maintained by stirring at high speed of 100 rpm 
(approximately) using a tiny magnetic bead the volume of 
receptor compartment was maintained at 60 ml and the 
diffusion surface are of 0.785 cm2. The receptor 
compartment was provided with the sampling port on one 
side, to withdraw sample at the predetermined time 
intervals[10] for estimation of drug content by UV 
spectrophotometer. 
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RESULTS 
 Physical Appearance 
All the prepared transdermal patches were uniform without 
any deformity. The patches were opaque. 
 Thickness Uniformity 
The average thickness of prepared film was found in the 
range of 0.02266 ± 0.0015 mm to 0.03533 ± 0.0025 
 Folding Endurance 
This test was performed to evaluate the flexibility of the 
films, the films were analysed by folding endurance studies. 
The values were in the range of 138 to 176 as seen in the 
formulation. This study uncovered the fact that the  films 
were capable to bear the mechanical pressure along with 
good flexibility.  
 Water Absorption Capacity 
IT is an important parameter which is very necessary in case 
if the patches are meant to be applied over the surface of the 
wound. This phenomenon is utilized to assess the capability 
of film to absorb wound exudates. The prepared film had 
tendency to absorb moisture effectively. 
 Percentage Moisture Loss 
The films are weighed accurately and kept in a desiccators 
containing anhydrous calcium chloride. After 3 days, the 
films were taken out and weighed. The maximum moisture 
loss was 4.3300 ± 0.0360 %  
 Tensile strength 
The maximum tensile strength was found to be 0.6130 ± 
0.0010 kg/cm2. 
 Drug content 
The drug content uniformity of all the formulations was 
determined. The results of the drug content in all the 
formulations were found to be in the range of 96 to 98 %. 
  In vitro Drug Release Studies 
The cumulative percentage of drug released in 12 h was 
found to be minimum and maximum for the formulations F4 
and F10 i.e. 81.023 ± 3.013 % and 98.564 ±3.005%. The in-
vitro release data obtained from different formulations of 
Glibenclamide was plotted for cumulative percent drug 
release versus time. 
 
Fig 1: In vitro drug dissolution studies of prepared 
patches 
DISCUSSION 
Transdermal drug delivery has had a rich past and is now 
emerging as a major alternative to other delivery systems. As 
this technique has matured and new fundamentals have been 
integrated into its development, new products and 
applications have shown new ways in which skin can play a 
larger part in healthcare and quality of life. Improved 
delivery has been shown for drugs of differing[11]. However, 
subjective and objective analysis of these devices is required 
to make sure scientific, regulatory and consumer needs are 
met. The devices in development are more costly and 
complicated compared with conventional transdermal patch 
therapies[12]. As such they could contain electrical and 
mechanical components that could increase the potential 
safety risks to patients owing to poor operator technique or 
device malfunction. In addition, effects of the device on the 
skin must be reversible, because any permanent damage to 
the stratum corneum will result in the loss of its barrier 
properties and hence its function as a protective organ[11]. 
Transdermal drug delivery provides some desirable 
performances over conventional pharmaceutical dosage 
formulations, such as avoiding gut and hepatic first-pass 
metabolism, improving drug bioavailability, reducing dose 
frequency, lessening the side effects and, thus, improved 
patient compliance[13]. From the above work it can be 
concluded that glibenclamide transdermal patches could be 
promising carrier in management of type 2 diabetes mellitus.  
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